Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries

T. Saida, T. Yamamura, T. Kondo, J. Yun, M. Yang, J. Li, L. Mahadavan, B. Zhu, SI. Sheikh,

. 2019 ; 19 (1) : 5. [pub] 20190107

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20015888

BACKGROUND: Delayed-release dimethyl fumarate (DMF) has demonstrated efficacy and a favorable benefit-risk profile in phase 2 and 3 studies that enrolled predominantly white patients with relapsing-remitting multiple sclerosis (RRMS). In this study (APEX, Part I), we evaluated the efficacy/safety outcomes of DMF in a predominantly East Asian population of patients with RRMS. METHODS: In this 24-week, randomized, double-blind, placebo-controlled phase 3 study, 225 patients, 142 of which were East Asian (63.4%), were enrolled: Japan (n = 114), South Korea (n = 20), Taiwan (n = 8), the Czech Republic (n = 42), and Poland (n = 40). Key exclusion criteria included diagnosis of neuromyelitis optica spectrum disorder. Stratified by country, patients were randomized 1:1 to receive DMF 240 mg twice daily or placebo. Clinical assessments, including neurological examination and EDSS scoring, were conducted at baseline and at weeks 12 and 24. RESULTS: A total of 213 patients (95.1%) completed the study. From weeks 12 - 24, the total number of new gadolinium-enhancing (Gd+) lesions was reduced by 84% (p < 0.0001) in DMF compared with placebo. For the secondary endpoint, from baseline to week 24, the total number of new Gd+ lesions was reduced by 75% and the mean number of new/newly enlarging T2 hyperintense lesions was reduced by 63% (both p < 0.0001). Flushing and flushing-related symptoms, and gastrointestinal events were adverse events related to DMF treatment. Efficacy and safety results in the Japanese subgroup and the East Asian subgroup (which included patients from Japan, Taiwan, and South Korea) were consistent with the overall study population. CONCLUSION: The strong efficacy and favorable benefit-risk profile of DMF extends to Japanese, and more broadly, East Asian patients with RRMS. TRIAL REGISTRATION: This trial is registered on ClinicalTrials.gov (identifier: NCT01838668 ), April 20, 2013 (retrospectively registered). The registration can be found at the following URL: https://clinicaltrials.gov/ct2/show/NCT01838668.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20015888
003      
CZ-PrNML
005      
20201119104846.0
007      
ta
008      
201012s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12883-018-1220-3 $2 doi
035    __
$a (PubMed)30616596
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Saida, Takahiko $u Kansai Multiple Sclerosis Centre, Kyoto Min-iren Central Hospital, Nishinokyo-Kasuga-cho 16-44-409, Nakakyo-ku, Kyoto, 604-8453, Japan. saida_takahiko@maia.eonet.ne.jp.
245    12
$a A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries / $c T. Saida, T. Yamamura, T. Kondo, J. Yun, M. Yang, J. Li, L. Mahadavan, B. Zhu, SI. Sheikh,
520    9_
$a BACKGROUND: Delayed-release dimethyl fumarate (DMF) has demonstrated efficacy and a favorable benefit-risk profile in phase 2 and 3 studies that enrolled predominantly white patients with relapsing-remitting multiple sclerosis (RRMS). In this study (APEX, Part I), we evaluated the efficacy/safety outcomes of DMF in a predominantly East Asian population of patients with RRMS. METHODS: In this 24-week, randomized, double-blind, placebo-controlled phase 3 study, 225 patients, 142 of which were East Asian (63.4%), were enrolled: Japan (n = 114), South Korea (n = 20), Taiwan (n = 8), the Czech Republic (n = 42), and Poland (n = 40). Key exclusion criteria included diagnosis of neuromyelitis optica spectrum disorder. Stratified by country, patients were randomized 1:1 to receive DMF 240 mg twice daily or placebo. Clinical assessments, including neurological examination and EDSS scoring, were conducted at baseline and at weeks 12 and 24. RESULTS: A total of 213 patients (95.1%) completed the study. From weeks 12 - 24, the total number of new gadolinium-enhancing (Gd+) lesions was reduced by 84% (p < 0.0001) in DMF compared with placebo. For the secondary endpoint, from baseline to week 24, the total number of new Gd+ lesions was reduced by 75% and the mean number of new/newly enlarging T2 hyperintense lesions was reduced by 63% (both p < 0.0001). Flushing and flushing-related symptoms, and gastrointestinal events were adverse events related to DMF treatment. Efficacy and safety results in the Japanese subgroup and the East Asian subgroup (which included patients from Japan, Taiwan, and South Korea) were consistent with the overall study population. CONCLUSION: The strong efficacy and favorable benefit-risk profile of DMF extends to Japanese, and more broadly, East Asian patients with RRMS. TRIAL REGISTRATION: This trial is registered on ClinicalTrials.gov (identifier: NCT01838668 ), April 20, 2013 (retrospectively registered). The registration can be found at the following URL: https://clinicaltrials.gov/ct2/show/NCT01838668.
650    _2
$a dospělí $7 D000328
650    _2
$a léky s prodlouženým účinkem $7 D003692
650    _2
$a dimethyl fumarát $x aplikace a dávkování $7 D000069462
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gadolinium $x aplikace a dávkování $7 D005682
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Česká republika $7 D018153
651    _2
$a Dálný východ $7 D005202
651    _2
$a Polsko $7 D011044
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Yamamura, Takashi $u NCNP, National Center Hospital, Tokyo, Japan.
700    1_
$a Kondo, Takayuki $u Kansai Medical University Medical Center, Osaka, Japan.
700    1_
$a Yun, Jang $u Biogen, Cambridge, MA, USA.
700    1_
$a Yang, Minhua $u Biogen, Cambridge, MA, USA.
700    1_
$a Li, Jie $u Biogen, Cambridge, MA, USA. Sanofi, Cambridge, MA, USA.
700    1_
$a Mahadavan, Lalitha $u Biogen, Cambridge, MA, USA. Faculty of Pharmaceutical Medicine, London, UK.
700    1_
$a Zhu, Bing $u Biogen, Cambridge, MA, USA.
700    1_
$a Sheikh, Sarah I $u Biogen, Cambridge, MA, USA.
773    0_
$w MED00008195 $t BMC neurology $x 1471-2377 $g Roč. 19, č. 1 (2019), s. 5
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30616596 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201012 $b ABA008
991    __
$a 20201119104843 $b ABA008
999    __
$a ok $b bmc $g 1584315 $s 1106056
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 19 $c 1 $d 5 $e 20190107 $i 1471-2377 $m BMC neurology $n BMC Neurol $x MED00008195
LZP    __
$a Pubmed-20201012

Najít záznam

Citační ukazatele

Možnosti archivace